CheckMate 511: 3-Year Follow-up of 2 Different Dosing Regimens of Nivolumab + Ipilimumab for Patients With Advanced Melanoma

June 4-8, 2021; Online at https://conferences.asco.org/am
Three-year follow-up of CheckMate 511 shows continued improved safety and comparable efficacy of NIVO3 + IPI1 vs NIVO1 + IPI3 for patients with advanced melanoma.
Format: Microsoft PowerPoint (.ppt)
File Size: 461 KB
Released: June 6, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Bristol-Myers Squibb
Pfizer, Inc.

Related Content

Dr Evan J. Lipson shares expert insights on the safety and efficacy of anti-LAG-3 immunotherapies in this webcast from Clinical Care Options (CCO)

Evan J. Lipson, MD Tian Zhang, MD, MHS Physicians: maximum of 0.75 AMA PRA Category 1 Credits Registered Nurses: 0.75 Nursing contact hours Pharmacists: 0.75 contact hours (0.075 CEUs) Released: April 20, 2022 Expired: April 19, 2023

Downloadable slideset on targeting LAG-3 in multiple tumor types and evidence on recently approved LAG-3 therapy, relatlimab, from Clinical Care Options (CCO)

Evan J. Lipson, MD Tian Zhang, MD, MHS Released: March 23, 2022

Downloadable PDF resource on LAG-3, safety and efficacy of approved anti-LAG-3 agent relatlimab, and clinical trial spotlight from Clinical Care Options (CCO)

Krista M. Rubin, MS, RN, FNP-BC Released: March 23, 2022

Downloadable slideset explaining the mechanism of action of LAG-3, from Clinical Care Options (CCO)

Released: March 22, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings